A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Hydrocodone | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Magnesium sulfate | The therapeutic efficacy of DPDPE can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | DPDPE may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Orphenadrine | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Pramipexole | DPDPE may increase the sedative activities of Pramipexole. |
| Ropinirole | DPDPE may increase the sedative activities of Ropinirole. |
| Rotigotine | DPDPE may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with DPDPE. |
| Sodium oxybate | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Thalidomide | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when DPDPE is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when DPDPE is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with DPDPE. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with DPDPE. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with DPDPE. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with DPDPE. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with DPDPE. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with DPDPE. |
| Naltrexone | The therapeutic efficacy of DPDPE can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with DPDPE. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with DPDPE. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with DPDPE. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with DPDPE. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with DPDPE. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with DPDPE. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with DPDPE. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Methadyl acetate is combined with DPDPE. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with DPDPE. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with DPDPE. |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with DPDPE. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with DPDPE. |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with DPDPE. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with DPDPE. |
| Desomorphine | The risk or severity of adverse effects can be increased when Desomorphine is combined with DPDPE. |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with DPDPE. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with DPDPE. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with DPDPE. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with DPDPE. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when DPDPE is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when DPDPE is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when DPDPE is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when DPDPE is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when DPDPE is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when DPDPE is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of DPDPE can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when DPDPE is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when DPDPE is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when DPDPE is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when DPDPE is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when DPDPE is combined with Naloxegol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when DPDPE is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with DPDPE. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with DPDPE. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with DPDPE. |
| Mirtazapine | DPDPE may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with DPDPE. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Alaproclate. |
| Ethanol | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | DPDPE may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of DPDPE. |
| Phentermine | Phentermine may increase the analgesic activities of DPDPE. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of DPDPE. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of DPDPE. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of DPDPE. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of DPDPE. |
| MMDA | MMDA may increase the analgesic activities of DPDPE. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of DPDPE. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of DPDPE. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of DPDPE. |